Lincosamides

Lincosamides are a class of antibiotics that includes lincomycin and its semisynthetic derivative clindamycin. They act by reversibly binding to the 50S ribosomal subunit of bacteria, near the peptidyl transferase center, and inhibit protein synthesis. Most lincosamides are bacteriostatic, though they can be bactericidal against certain organisms at high concentrations or in high bacterial loads.

The agents have good activity against gram-positive cocci and a broad spectrum of anaerobic bacteria, including many Bacteroides species, but show limited activity against gram-negative aerobes and enteric rods. Clinically, lincosamides are used for mixed infections, skin and soft tissue infections, gynecological and intra-abdominal infections, and as an option for dental prophylaxis in penicillin-allergic patients. Clindamycin is also widely used topically for acne and marginally penetrates bone and abscess cavities, making it useful in certain osteoarticular infections.

Pharmacokinetics and administration vary by agent. Clindamycin is well absorbed orally, distributes widely (including to bone and pus), undergoes hepatic metabolism, and is excreted in bile and urine with a half-life of about 2–3 hours. It can be given orally, IV, or IM, with dosing adjusted for severity of infection and patient factors.

Resistance mechanisms include ribosomal target modification by erm methylases (leading to MLSB cross-resistance with macrolides) and enzymatic inactivation or efflux. Adverse effects include gastrointestinal upset and Clostridioides difficile–associated diarrhea; hypersensitivity reactions and rare hepatotoxicity can occur. Caution is advised in patients with active colitis or severe hepatic impairment, and clinicians should consider local resistance patterns when selecting therapy. Lincomycin and clindamycin exemplify the lincosamides’ medical utility and limitations.